Last updated: February 15, 2026
What is NDC 81298-8110?
NDC 81298-8110 is a medication marketed by Novavax as NVX-CoV2373, a protein subunit COVID-19 vaccine. It received Emergency Use Authorization (EUA) from the FDA in July 2022 and full approval in July 2023. Its primary indications are for active immunization to prevent COVID-19 in individuals aged 12 years and older.
Market Dynamics and Competitive Landscape
Market Size and Demand Drivers
- Global COVID-19 vaccine market estimated at $43.3 billion in 2022, projected to decline as pandemic response shifts to endemic management (Source: Statista).
- In the U.S., approximately 255 million COVID-19 vaccine doses administered as of Q4 2022; demand stabilized but remains significant in specific populations (CDC).
- Novavax's vaccine competes primarily with mRNA vaccines from Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax), which dominate the market due to early approval and higher distribution.
Key Competitors and Market Share
| Vaccine |
Type |
Estimated Market Share (Q4 2022) |
Features |
| Pfizer-BioNTech |
mRNA |
55% |
High efficacy, established logistics |
| Moderna |
mRNA |
38% |
Robust immunogenicity |
| Novavax (NVX-CoV2373) |
Protein subunit |
5% |
Favorable storage profile, traditional platform |
Regulatory and Supply Status
- Limited initial supply compared to mRNA rivals.
- FDA approval advances confidence but supply chain constraints and vaccination hesitancy impact rollout.
Geographical Market Penetration
- U.S. prioritizes vaccination for vulnerable populations.
- Supplies in Canada and select European nations expand in late 2022 and early 2023.
- Emerging markets show slower adoption due to infrastructure and cost considerations.
Price Projections and Economic Considerations
Current Pricing
- In the U.S., publicly listed prices for NVX-CoV2373 are approximately $28–$30 per dose for government procurement, with private payers negotiating discounts.
- Federal contracts initially set the price at $19.50 per dose, with plans to reduce as manufacturing scales.
Price Trends
| Year |
Estimated Price per Dose |
Comments |
| 2022 |
$19.50–$30 |
Initial distribution agreements |
| 2023 |
$15–$25 |
Increasing manufacturing capacity |
| 2024 |
$12–$20 |
Competitive pressure from mRNA vaccines |
Long-Term Price Projections
- As supply increases and competition intensifies, prices could decline to $10–$15 per dose by 2025.
- Potential for tiered pricing in emerging markets, possibly reducing to less than $10 per dose.
Cost-Benefit Analysis
- Lower manufacturing costs due to traditional protein approach.
- Reduced cold chain requirements (2°C to 8°C), increasing its attractiveness in resource-limited settings.
- Potential for government subsidies and bulk purchasing agreements to lower final consumer prices.
Future Market Opportunities and Risks
Opportunities
- Broader age approvals could expand the target population.
- Booster doses and variant-specific formulations may sustain demand.
- Partnerships with global health agencies (e.g., COVAX) can open new markets.
Risks
- Dominance of mRNA vaccines limits market share growth.
- Possible emergence of new variants affecting vaccine efficacy.
- Regulatory hurdles in international markets.
- Public perception influenced by reports of adverse effects or efficacy concerns.
Conclusion
NDC 81298-8110, NVX-CoV2373, captures a modest share of the COVID-19 vaccine market due to competitive pressures but benefits from stability, lower cold chain requirements, and a traditional platform appealing to specific demographics. Price projections suggest a downward trend over the next two to three years, driven by increased production capacity and market competition. Its long-term success hinges on expanding indications, overcoming competitive barriers, and establishing a presence in emerging markets.
Key Takeaways
- NDC 81298-8110 is a protein subunit COVID-19 vaccine, with initial prices around $19.50 per dose.
- The global COVID-19 vaccine market is still sizable but faces declining demand as the pandemic transitions to endemic stages.
- Market share remains limited compared to mRNA vaccines but growing in specific regions with supply chain advantages.
- Price reductions to $10–$15 per dose are anticipated by 2025 as manufacturing scales and competition increases.
- Opportunities exist in booster formulations and emerging markets, but market share growth remains constrained by dominant mRNA players and variant efficacy concerns.
FAQs
1. What factors influence the price of NDC 81298-8110?
Manufacturing costs, supply chain scale, competition, regulatory approvals, and negotiations with government and private payers influence pricing.
2. How does NVX-CoV2373 compare to mRNA vaccines?
It has a traditional protein subunit platform, requires less stringent cold storage, and may appeal to vaccine-hesitant populations.
3. What is the estimated market share for NVX-CoV2373 in 2023?
Approximately 5%, primarily in markets where supply constraints or logistical advantages favor its use.
4. What are the risks to market expansion for this vaccine?
Strong market dominance by mRNA vaccines, efficacy concerns against new variants, and regulatory or supply chain hurdles.
5. Could NVX-CoV2373 replace mRNA vaccines?
Unlikely in the short term due to market penetration levels. It may complement existing options, especially in regions with specific logistical needs.
References
- Statista. COVID-19 vaccine market size, 2022.
- CDC. COVID-19 vaccination data, Q4 2022.
- FDA. Emergency Use Authorization and approval summaries for NVX-CoV2373.
- Novavax. Product information and quarterly reports.
- MarketWatch. COVID-19 vaccine market projections, 2023–2025.
